[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FI946104A - Erittäin konsentroitu immunoglobuliinivalmiste ja menetelmä sen valmistamiseksi - Google Patents

Erittäin konsentroitu immunoglobuliinivalmiste ja menetelmä sen valmistamiseksi Download PDF

Info

Publication number
FI946104A
FI946104A FI946104A FI946104A FI946104A FI 946104 A FI946104 A FI 946104A FI 946104 A FI946104 A FI 946104A FI 946104 A FI946104 A FI 946104A FI 946104 A FI946104 A FI 946104A
Authority
FI
Finland
Prior art keywords
preparation
particularly concentrated
concentrated immunoglobulin
immunoglobulin
highly concentrated
Prior art date
Application number
FI946104A
Other languages
English (en)
Swedish (sv)
Other versions
FI946104A0 (fi
FI111224B (fi
Inventor
Johann Eibl
Yendra Linnau
Wolfgang Teschner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6506449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI946104(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI946104A0 publication Critical patent/FI946104A0/fi
Publication of FI946104A publication Critical patent/FI946104A/fi
Application granted granted Critical
Publication of FI111224B publication Critical patent/FI111224B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI946104A 1993-12-28 1994-12-27 Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi FI111224B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4344824 1993-12-28
DE4344824A DE4344824C1 (de) 1993-12-28 1993-12-28 Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Publications (3)

Publication Number Publication Date
FI946104A0 FI946104A0 (fi) 1994-12-27
FI946104A true FI946104A (fi) 1995-06-29
FI111224B FI111224B (fi) 2003-06-30

Family

ID=6506449

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946104A FI111224B (fi) 1993-12-28 1994-12-27 Menetelmä erittäin konsentroidun immunoglobuliinivalmisteen valmistamiseksi

Country Status (15)

Country Link
US (1) US5608038A (fi)
EP (1) EP0661060B1 (fi)
JP (1) JP3040678B2 (fi)
AT (2) AT407707B (fi)
CA (1) CA2138853A1 (fi)
CZ (1) CZ284186B6 (fi)
DE (2) DE4344824C1 (fi)
DK (1) DK0661060T3 (fi)
ES (1) ES2158877T3 (fi)
FI (1) FI111224B (fi)
HR (1) HRP941018B1 (fi)
HU (1) HU220766B1 (fi)
NO (1) NO315260B1 (fi)
RU (1) RU2104713C1 (fi)
YU (1) YU77994A (fi)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
CN1151842C (zh) 1995-07-27 2004-06-02 基因技术股份有限公司 稳定等渗的冻干蛋白制剂
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
IL133220A0 (en) * 1997-06-13 2001-03-19 Genentech Inc Stabilized antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20060182740A1 (en) * 2002-06-21 2006-08-17 Biogen Idec, Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
HUE030579T2 (en) * 2003-04-04 2017-05-29 Genentech Inc High Concentration Antibody And Protein Products
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CN101048427B (zh) * 2004-07-23 2015-01-14 健泰科生物技术公司 抗体或其片段的结晶
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP2142565A4 (en) 2007-03-29 2010-03-31 Abbott Lab CRYSTALLINE HUMAN ANTI-IL-12 ANTIBODIES
SG10201604258YA (en) * 2007-11-30 2016-07-28 Abbvie Biotechnology Ltd Anti-tnf antibody formulations
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
NZ606283A (en) * 2008-11-28 2014-08-29 Abbvie Inc Stable antibody compositions and methods for stabilizing same
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
WO2010102241A1 (en) * 2009-03-06 2010-09-10 Genentech, Inc. Antibody formulation
EP2477603B1 (en) 2009-09-17 2016-03-30 Baxalta Incorporated Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
DK2542257T3 (en) 2010-03-01 2017-10-16 Bayer Healthcare Llc OPTIMIZED MONOCLONAL ANTIBODIES AGAINST Tissue FACTOR ROAD INHIBITOR (TFPI)
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
JP6412575B2 (ja) 2013-09-11 2018-10-24 イーグル バイオロジクス， インコーポレイテッド 有機ホスフェートを含有する液状タンパク質製剤
US10568951B2 (en) 2013-11-18 2020-02-25 Formycon Ag Pharmaceutical composition of an anti-VEGF antibody
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3200804A4 (en) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2599029C1 (ru) * 2015-07-16 2016-10-10 Игорь Геннадьевич Ковшик Химерный иммуноглобулиновый препарат, обладающий специфическим противовирусным или антибактериальным действием
LT3334747T (lt) 2015-08-13 2023-12-27 Amgen Inc. Įkrautas giluminis antigeną surišančio baltymo filtravimas
EA201990998A1 (ru) 2016-10-21 2019-11-29 Фармацевтические составы и способы их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075193A (en) * 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
JPS57203017A (en) * 1981-06-09 1982-12-13 Fujirebio Inc Purifying method of immunoglobulin
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763C (da) * 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
ATE59144T1 (de) * 1984-07-07 1991-01-15 Armour Pharma Gmbh Verfahren zur herstellung von gamma-globulin zur intravenoesen anwendung.
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
US5248767A (en) * 1986-06-11 1993-09-28 Behringwerke Aktiengesellschaft Process for the preparation of a pasteurized immunoglobulin preparation using ethanol
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.

Also Published As

Publication number Publication date
JPH07206709A (ja) 1995-08-08
YU77994A (sh) 1997-03-07
ATE201328T1 (de) 2001-06-15
CZ284186B6 (cs) 1998-09-16
DE59409761D1 (de) 2001-06-28
ATA237894A (de) 2000-10-15
HRP941018B1 (en) 1999-12-31
US5608038A (en) 1997-03-04
CZ328494A3 (en) 1995-07-12
DE4344824C1 (de) 1995-08-31
AT407707B (de) 2001-05-25
EP0661060A3 (de) 1997-01-15
DK0661060T3 (da) 2001-07-30
EP0661060B1 (de) 2001-05-23
RU2104713C1 (ru) 1998-02-20
HU220766B1 (hu) 2002-05-28
NO315260B1 (no) 2003-08-11
NO945045D0 (no) 1994-12-27
HRP941018A2 (en) 1997-04-30
FI946104A0 (fi) 1994-12-27
JP3040678B2 (ja) 2000-05-15
EP0661060A2 (de) 1995-07-05
HUT70449A (en) 1995-10-30
CA2138853A1 (en) 1995-06-29
HU9403795D0 (en) 1995-02-28
ES2158877T3 (es) 2001-09-16
FI111224B (fi) 2003-06-30
NO945045L (no) 1995-06-29

Similar Documents

Publication Publication Date Title
FI946104A (fi) Erittäin konsentroitu immunoglobuliinivalmiste ja menetelmä sen valmistamiseksi
AU5612694A (en) Injectable composition
DK0812198T3 (da) Stabilisering af prostaglandinpræparater
ZA924999B (en) New compositions containing taxane derivatives
DE69212921D1 (de) Sonnenschutzmittel
ATE68704T1 (de) Gegenueber lichteinfluss stabilisiertes nifedipin- konzentrat und verfahren zu seiner herstellung.
FR2635780B1 (fr) Diorganopolysiloxane a fonction benzotriazole
DE69314942D1 (de) N-acylglutamin-derivate
BR9401198A (pt) Massas de polietileno
PH27567A (en) Topical compositions
YU46914B (sh) Metoksimetilna jedinjenja
KR910000901A (ko) 폴리에틸렌 조성물
PT97663A (pt) Processo de preparacao de 3'-desamino-4'-desoxi-4'-amino-8-fluoro-antraciclinas, de composicoes farmaceuticas que as contem e de seus intermediarios
ES2021334B3 (es) Composiciones de caucho que contienen derivados aminicos del 1,3,4-triadiazol.
KR890003380A (ko) 피부에 축적하는 외용의 항 바이러스성 약학적 조성물 및 그 제조방법
DE3586286D1 (de) Verwendung von pyrrothinderivaten.
AU1508592A (en) Sweetening agents derived from l-glutamic acid and their method of preparation
DK0533089T3 (da) Flydende peroxidiske sammensætninger
KR900012969A (ko) 신규한 방향족 폴리에스테르 화합물
KR870008535A (ko) "밤"가루(율분)
KR910009258A (ko) 니트록시닐과 레바미솔 복합주사제의 제조방법

Legal Events

Date Code Title Description
MA Patent expired